European Archives - Page 479 of 1019 - European Medical Journal

The expectation vs reality of drug launch

This infographic reviews drug launches from recent years, comparing the expectation vs reality of launch, the increase in first-time launchers, and the impact of COVID-19 on the landscape.

Editor's Pick: Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);1 as of September 2020, there were >33 million…

Autosomal Dominant Polycystic Kidney Disease in Children

In this webinar focusing on Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Children, Djalila Mekhali, University Hospital of Leuven, Belgium, presents a comprehensive account of the disease and its progression.

A Way to Diagnose Protein Energy Wasting in Children with Kidney Disease

CHILDREN with kidney disease are vulnerable to protein energy wasting (PEW), reported an observational study from St John’s National Academy of Health Sciences, Bangalore, India.

Hospitalised Patients with COVID-19 and Kidney Disease

PATIENTS hospitalised due to COVID-19 with end-stage renal disease (ESRD) showed better outcomes than patients with non-dialysis chronic kidney disease (CKD), an observational, retrospective study from New York City, New York, USA, reported.

EMJ Podcast: Surgery and Synchrodestiny

Jonathan sits down with Dr Shailesh Vadodaria, Consultant Aesthetic Plastic Surgeon, MACS Clinic, London to discuss the rising cases of gynecomastia, reflect on his missionary and charity projects, and explore spirituality and synchrodestiny.

Talking to Sir Clive Woodward part 2

Sir Clive Woodward, Former England Rugby Coach, discusses the importance of teams having aligned values and the rules of teamship.

Webinar: Diclofenac in a New and Innovative Form: Low Dosages and Small Volume

In this webinar Dr. Jonathan Sackier is joined by Dr. Alia Darweish Medniuk and Dr. Juraj Kacian as they discuss the importance of the NSAID diclofenac for the management of pain in different settings/clinical situations. They will also highlight what’s new for diclofenac, namely the development of new formulations at small volume and low dosages, in line with the EMA recommendations on NSAIDs and CV risk

Improvements and Shortcomings in Emergency Oxygen Prescribing: A Quality Improvement Initiative at an Acute Tertiary Care Hospital

There have been seven national audits looking at the prescription of oxygen, the largest of which was the 2015 British Thoracic Society (BTS) Audit…

Musculoskeletal Brucellosis in Adults in the United Arab Emirates: A Retrospective Study

Brucellosis is a zoonotic infection, historically known as Maltese fever, caused by aerobic Gram-negative coccobacilli, which was first identified by Sir…